Products for Research Use Only
RegisterLogin

Enoticumab

CAT: 0804-HY-P99925-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99925-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively[1].
CAS Number
1192578-27-0
Product Name Alternative
REGN421
UNSPSC
12352203
Target
Notch
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/enoticumab.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[Enoticumab]
Molecular Weight
(146.48 kDa)
References & Citations
[1]Kuhnert F, Chen G, Thurston G. Potent anti-tumor activity of blocking stromal Dll4 in ovarian xenograft models[J]. Cancer Research, 2013, 73 (8_Supplement) : 5091-5091.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1

Related Products

CatalogName
HY-P99193-01Enokizumab

Alternative Products

CatalogName
abx831248-01Enoticumab
GTR18333946-01Enoticumab Antibody
591835Enoticumab (DLL4)
MBS1563941-01Research Grade Enoticumab
C00606-1mg*5Enoticumab (Anti-DLL4)
047718DLL4 (enoticumab) discontinued
E55B0557Enoticumab (Reference antibody)
ICH5526-10mgEnoticumab Biosimilar - Research Grade
F1543-50Anti-DLL4 Antibody (Enoticumab)
GTR18697614-01Enoticumab Human Monoclonal Antibody

Popular Products